Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes

Author:

Tray, Nancy

Taff, Jessica

Singh, Baljit

Suh, James

Ngo, Nhu

Kwa, Maryann

Troxel, Andrea B

Chae, Young Kwang

Kurzrock, Razelle

Patel, Sandip Pravin

Sharon, Elad

Denkert, Carsten

Ross, Jeffrey S

Adams, Sylvia
Author Address

NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA., White Plains Hospital, White Plains, NY, USA., Frederick National Laboratory for Cancer Research, Rockville, MD, USA., Foundation Medicine, Inc., Cambridge, MA, USA., NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU School of Medicine, USA., Northwestern University Feinberg School of Medicine, Chicago, IL, USA., UC San Diego Moores Cancer Center, La Jolla, CA, USA., Division of Cancer Treatment & Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Institute of Pathology, Charit 233; University Hospital, Berlin, Germany., NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA. Electronic address: sylvia.adams@nyulangone.org.,

Abstract:

Metaplastic breast cancer (MPBC) is a rare subtype that accounts for < 1% of all breast cancers. Although these are typically "triple negative," they are relatively chemotherapy-refractory compared to conventional triple negative invasive breast cancers with more aggressive features and an overall poor prognosis. MPBC is a heterogeneous group of tumors that are enriched for TP53 and PIK3CA mutations, and have been found to have high PD-L1 expression though the mechanisms underlying its immunogenicity remain unclear. We perform comprehensive genomic profiling in the largest MPBC dataset (n = 192) to date and assess for other potential biomarkers of immune response. (C) 2018 Elsevier Ltd. All rights reserved.

See More

Author Address